Dofetilide
- TRADE NAME: Tikosyn (Pfizer)
- INDICATIONS: Conversion of atrial fibrillation and atrial flutter to normal sinus rhythm
- CLASS: Antiarrhythmic, Antiarrhythmic class III
- HALF-LIFE: 10 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Chlorpromazine, Cimetidine, Co-Trimoxazole, Degarelix, Dolutegravir, Fluphenazine, Hydrochlorothiazide, Itraconazole, Ketoconazole, Medroxyprogesterone, Megestrol, Mesoridazine, Phenothiazines, Prochlorperazine, Progestins, Promethazine, Quinine, Ranolazine, Thioridazine, Trifluoperazine, Trilaciclib, Trimethoprim, Vandetanib, Verapamil, Voriconazole, Zuclopenthixol
PREGNANCY CATEGORY: C
Contra-indicated in patients with congenital or acquired long QT syndromes.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
